You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 12, 2025

Suppliers and packagers for nilutamide


✉ Email this page to a colleague

« Back to Dashboard


nilutamide

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant Tradename Generic Name Dosage NDA NDA/ANDA Supplier Package Code Package Marketing Start
Ani Pharms NILUTAMIDE nilutamide TABLET;ORAL 207631 ANDA ANI Pharmaceuticals, Inc. 62559-173-31 3 BLISTER PACK in 1 CARTON (62559-173-31) / 10 TABLET in 1 BLISTER PACK 2016-07-18
>Applicant >Tradename >Generic Name >Dosage >NDA >NDA/ANDA >Supplier >Package Code >Package >Marketing Start

Suppliers for the Pharmaceutical Drug: Nilutamide

Last updated: July 29, 2025


Introduction

Nilutamide is a non-steroidal antiandrogen primarily employed in the treatment of prostate cancer. As an essential component in oncological therapy, its supply chain is critical to ensure consistent availability for physicians and patients worldwide. This report provides a comprehensive overview of the primary suppliers of Nilutamide, highlighting manufacturing sources, global distribution channels, and considerations for stakeholders seeking reliable procurement options.


Overview of Nilutamide

Developed in the late 20th century, Nilutamide (chemical name: N-[(3S)-4,4-dimethyl-3-(trifluoromethyl)thiochroman-2-yl]propane-2-sulfonamide) functions as an androgen receptor antagonist. Its role is predominantly in combination with other therapies for advanced prostate carcinoma. Although generic formulations are common, the drug's manufacture hinges on specialized chemical synthesis and stringent quality controls, making supplier identification essential for compliance and efficacy.


Primary Suppliers and Manufacturers

1. Origin and Parity of Patent and Market Authorization

Since patent expiry in most jurisdictions, several generic pharmaceutical companies have entered the Nilutamide market. The landscape varies significantly across regions, with some countries relying on local manufacturers, and others importing from global generic producers or original patent holders.

2. Leading Manufacturers and Suppliers in the Global Market

a. MNCs and Well-Established Pharmaceutical Companies

  • Bayer AG: Historically a pioneer in various chemotherapeutic agents, Bayer has supplied related antiandrogens, though Nilutamide is not its current portfolio. Nonetheless, Bayer's extensive manufacturing capabilities mean it remains a potential supplier or partner for licensing agreements.

  • Teva Pharmaceutical Industries: As one of the world's largest generic manufacturers, Teva supplies numerous antiandrogens, including Nilutamide, in various markets, especially in Asia and Europe.

  • Sandoz (Novartis): Known for generic drugs, Sandoz has the infrastructure to produce Nilutamide with high compliance to quality standards, particularly for the European and North American markets.

  • Cipla Ltd.: An Indian pharmaceutical major offering affordable generics, Cipla supplies Nilutamide in certain markets, leveraging cost-efficient manufacturing.

b. Regional and Local Manufacturers

In addition to multinational corporations, several regional generic companies manufacture Nilutamide owing to local demand and regulatory approvals:

  • Shanghai Acebright Pharmaceuticals: Based in China, they produce a broad portfolio of oncological drugs, including Nilutamide, primarily catering to the Asian markets.

  • Yenisei Pharmaceutical: Russia-based, supplying antiandrogens, including Nilutamide, to Eastern European and CIS nations.

  • Hetero Drugs: India-based manufacturer with a significant portfolio of cancer therapies.


Regulatory and Certification Standards

Manufacturers must adhere to Good Manufacturing Practices (GMP) and obtain approvals from respective regulatory agencies such as the FDA (U.S. Food and Drug Administration), EMA (European Medicines Agency), or national agencies. Suppliers compliant with these standards ensure pharmaceutical safety and efficacy.


Distribution Channels and Procurement Considerations

1. Direct Procurement from Manufacturers

Large healthcare institutions and governments often negotiate directly with manufacturers, especially for bulk purchases. Such arrangements typically involve licensing agreements, quality assurance protocols, and supply chain logistics.

2. Authorized Distributors and Wholesalers

Third-party distributors facilitate supply to regions with limited direct manufacturer presence. It is crucial to verify their authorization status and compliance with regulatory standards to mitigate risks of counterfeit or substandard products.

3. Online and Marketplaces

While online platforms may offer Nilutamide, legitimacy and product quality verification are critical to prevent counterfeit medicines. Procurement via reputable suppliers with verified certifications remains essential.


Emerging Trends and Challenges

  • Global Supply Chain Disruptions: COVID-19 and geopolitical tensions have impacted manufacturing and logistics, heightening the importance of diversified supplier networks.

  • Regulatory Harmonization: Enhanced regulatory cooperation aims to streamline approvals and compliance across jurisdictions, benefiting supply consistency.

  • Generic Market Expansion: Increased demand for affordable cancer therapies supports the proliferation of regional manufacturers, expanding supplier options for Nilutamide.


Conclusion

The supply of Nilutamide is multifaceted, relying on a network of global and regional manufacturers, each subject to varying regulatory landscapes. Reliable procurement hinges on selecting suppliers with proven manufacturing quality, regulatory approvals, and robust distribution channels. Stakeholders should prioritize contractual clarity, quality assurance, and compliance, especially amid ongoing supply chain challenges.


Key Takeaways

  • Major suppliers include Teva, Sandoz, Cipla, Shanghai Acebright, Yenisei Pharma, and Hetero Drugs.

  • The competitive landscape favors generic manufacturers post-patent expiry, expanding supplier options.

  • Ensuring supplier GMP compliance and regulatory approvals is critical to mitigate risks.

  • Diversified sourcing strategies can buffer against supply chain disruptions.

  • Regional manufacturers dominate certain markets, emphasizing the importance of localized supplier validation.


FAQs

1. Is Nilutamide available from multiple suppliers globally?
Yes, following patent expiration, several generic companies, especially in India, China, Russia, and Europe, manufacture Nilutamide, providing a diversified supplier base.

2. How can I verify the authenticity of Nilutamide from a supplier?
Request manufacturer certifications, GMP compliance documents, and regulatory approvals. Purchasing from authorized distributors and reputable pharmacies also reduces counterfeit risks.

3. Are there regional restrictions on Nilutamide supply?
Regulatory approval varies; some countries may prohibit or restrict import due to regulatory differences. Verify local guidelines before procurement.

4. How does supply chain disruption affect Nilutamide availability?
Pandemics, political instability, and logistical issues can cause shortages, emphasizing the importance of multiple, reliable suppliers for continuous access.

5. Can I procure Nilutamide directly from original patent holders?
Generally, original patent holders may license production or sell directly in specific markets; however, most supplies are now generics from approved manufacturers.


Sources

[1] Drug Information Portal, U.S. National Library of Medicine.
[2] World Health Organization. GMP Compliance Reports.
[3] European Medicines Agency. Market Authorizations.
[4] Company Websites and Press Releases.
[5] Pharmaceutical Market Reports 2023.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.